Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile ...

U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Nabla Bio partners with Takeda to use its AI platform JAM for designing antibodies, receiving upfront payments and potential ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) presented initial data from its ongoing RESET-PV™ trial evaluating rese ...

Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory ...

Cabaletta Bio (CABA) presented initial dose data from the RESET-PV trial evaluating rese-cel at 1 x 106 cells/kg without preconditioning in three evaluable patients with pemphigus vulgaris. These data ...

Adicet Bio reported strong Phase 1 lupus trial results with ADI-001, showing 100% response in nephritis patients and raising ...

Braskem’s I’m green™ bio-based brand will participate in Sustainable Brands 2025, held in San Diego, Calif., from Oct. 13 to ...

Amid an increasing focus by the design community, end users and consumers, more suppliers are bringing PVC-free resilient ...